Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Textual)

v3.21.1
Subsequent Events (Details Textual) - USD ($)
3 Months Ended
May 08, 2021
Jan. 21, 2021
Mar. 31, 2021
Subsequent Event [Line Items]      
Granted (in shares)     66,300
Grants in period, weighted average exercise price (in dollars per share)     $ 9.74
Fair value assumptions, expected dividend payments   $ 0  
Merger Agreement | AbbVie Inc. | Subsequent Event      
Subsequent Event [Line Items]      
Merger related costs, cash paid per share $ 22.60    
Termination fees $ 18,625,000    
Reverse termination fees $ 20,000,000    
Share-based Payment Arrangement, Option      
Subsequent Event [Line Items]      
Expiration term period   10 years  
Award vesting rights, percentage   25.00%  
Award vesting period   4 years  
Aggregate grant date fair value   $ 2,500,000 $ 500,000
Discount rate   1.03%  
Initial award option purchasing term   6 years 3 months  
Fair value assumptions, expected volatility rate   90.77%  
Fair value assumptions, expected dividend payments     $ 0
Share price (in dollars per share)   $ 16.47  
Certain Individuals      
Subsequent Event [Line Items]      
Granted (in shares)   345,350 66,300
Grants in period, weighted average exercise price (in dollars per share)   $ 9.74 $ 9.74